XSHG
600315
Market cap1.84bUSD
Oct 09, Last price
19.45CNY
1D
5.14%
1Q
10.01%
Jan 2017
-28.26%
IPO
425.68%
Name
Shanghai Jahwa United Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Jahwa United Co., Ltd., established in 1898 in Shanghai, People's Republic of China (and formerly known as HK Kwong Sang Hong), is a leading manufacturer and distributor of skin care, personal care, and home care products. Primarily serving the Chinese market, the company offers a comprehensive range of items, including a diverse selection of cosmetics, perfumes, and fragrances, various hair and body care solutions, specialized products for infant and mother care, household cleaning essentials, and dermatologist-recommended treatments. These offerings are marketed through numerous recognized brands such as VIVE, Maxam, Liushen, Herborist, Dr. Yu, GIVING, and Tommee Tippee, among others. Shanghai Jahwa distributes its products through a robust network that includes its own e-commerce channels, dedicated cosmetics specialty stores, department stores, and supermarkets.
Key people
Yongtao Luo
Chief Financial Officer, Secretary of the Board · since 2025
Xiaohai Lin
Chairman of the Board, Chief Executive Officer, General Manager · since 2024
Yang Cao
Chief Human Resources Officer, Staff Elected Director · since 2025
Minghui Deng
Director · since 2015
Dong Liu
Director · since 2015
Hongqing Xu
Director · since 2025
Jianxin Cheng
Non-Executive Director · since 2024
Guohua Feng
Independent Director · since 2020
Minghui Li
Independent Director · since 2025
Xiaobin Liu
Independent Director · since 2025
Lujun Wang
Independent Director · since 2018
Haitong Xia
Independent Non-Executive Director · since 2024
Lirong Xiao
Independent Non-Executive Director · since 2022
Headquarters & legal address
上海市保定路527号
浦东新区, SH 200000
CN
浦东新区, SH 200000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||